Short Interest in ImmuCell Corporation (NASDAQ:ICCC) Grows By 40.4%

ImmuCell Corporation (NASDAQ:ICCC) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 10,924 shares, a growth of 40.4% from the December 31st total of 7,780 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 27,377 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 27,377 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of ImmuCell in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

ImmuCell Trading Up 1.5%

Shares of ICCC opened at $6.11 on Tuesday. ImmuCell has a 1-year low of $4.28 and a 1-year high of $7.60. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The firm’s 50-day moving average price is $5.98 and its 200-day moving average price is $6.10. The firm has a market capitalization of $55.30 million, a price-to-earnings ratio of 23.50 and a beta of 0.30.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The company had revenue of $5.51 million during the quarter.

Institutional Trading of ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC bought a new position in ImmuCell Corporation (NASDAQ:ICCC) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned approximately 0.35% of ImmuCell at the end of the most recent quarter. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.